Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Nov;103(5):460-471.
doi: 10.1111/ejh.13295. Epub 2019 Sep 4.

Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms

Wolfgang Knauf  1 , Wolfgang Abenhardt  2 , Johannes Mohm  3 , Jacqueline Rauh  4 , Johanna Harde  5 , Anja Kaiser-Osterhues  6 , Martina Jänicke  7 , Norbert Marschner  8 ; TLN-Group (Tumour Registry Lymphatic Neoplasms)
Affiliations
Randomized Controlled Trial

Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms

Wolfgang Knauf et al. Eur J Haematol. 2019 Nov.

Abstract

Objectives: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL). Dose-dense two-weekly 'R-CHOP-14' was not superior over three-weekly 'R-CHOP-21' in randomised clinical trials (RCTs). We present real-world data on effectiveness of R-CHOP-14 and R-CHOP-21 in patients with DLBCL treated in German routine practice.

Methods: We identified 582 patients with DLBCL treated with R-CHOP-14 or R-CHOP-21 in 92 sites from the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms. Patients' schedules were classified by (a) length of the initial first cycle and (b) length of cycles 1-4.

Results: About 55% of patients received R-CHOP-21, 45% R-CHOP-14, in median 6 cycles. 51% and 55% of patients, respectively, were able to continue their initial R-CHOP-14 and R-CHOP-21 schedule. While most characteristics between the patient cohorts were similar, patients receiving R-CHOP-21 presented slightly more often with tumour stage I and lower IPI risk. 3-year overall survival of patients with R-CHOP-14 and R-CHOP-21 did not differ: 84% vs 84% (first cycle), 87% vs 89% (cycles 1-4).

Conclusions: Patients with DLBCL in Germany are slightly more likely to receive R-CHOP-21 than R-CHOP-14. Both schedules are similarly effective in routine practice confirming the results from RCTs.

Keywords: cohort studies; cyclophosphamide; diffuse large B-cell lymphoma; doxorubicin; outpatients; prednisone; prognosis; registries; rituximab; vincristine.

PubMed Disclaimer

References

REFERENCES

    1. Robert Koch-Institut; Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., (eds). Krebs in Deutschland 2013/2014. Häufigkeiten und Trends. 11. Ausgabe. Berlin, Germany: Robert Koch-Institut; 2017.
    1. Vidal L, Shpilberg O, Gurion R, et al. CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma - a meta-analysis of randomized controlled trials. Acta Oncol Stockh Swed. 2015;21:1-8.
    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
    1. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
    1. Kühnl A, Cunningham D, Counsell N, et al. Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol. 2017;28(7):1540-1546.

Publication types

MeSH terms

LinkOut - more resources